Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 20/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20872624 | 0.82 | OPRK1 (0.51) | OPRK1 | |
| SCHEMBL15636128 | 0.82 | OPRK1 (0.48) | OPRK1 | |
| SCHEMBL20472389 | 0.82 | OPRK1 (0.48) | OPRK1 | |
| SCHEMBL29988045 | 0.81 | OPRK1 (0.50) | OPRK1 | |
| SCHEMBL20889335 | 0.81 | OPRK1 (0.50) | OPRK1 | |
| SCHEMBL1886755 | 0.81 | OPRK1 (0.50) | OPRK1 | |
| SCHEMBL30989841 | 0.81 | OPRK1 (0.50) | OPRK1 | |
| SCHEMBL31032874 | 0.81 | CA12 (0.49) | — | |
| SCHEMBL29517846 | 0.81 | OPRK1 (0.50) | OPRK1 | |
| SCHEMBL3699766 | 0.81 | OPRK1 (0.50) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4423068-B1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-20250011288-A1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-01-09 | — | — | US | disclosed |
| EP-4423068-A1 | RXFP1 AGONISTS | Bristol-Myers Squibb Company (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118510758-A | RXFP1 agonists | 百时美施贵宝公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-116916914-A | SOS1 inhibitors and uses thereof | 锐新医药公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-112262139-B | Aminopyrrolotriazines as kinase inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| WO-2010100475-A1 | HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2010-09-10 | — | — | WO | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| EP-1937682-A1 | MET KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007041379-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041379-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | OPRK1 2875/4885 |
| US-20070078140-A1 | MET kinase inhibitors | MET, ABL1, ERBB2 | OPRK1 2034/4885 |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | OPRK1 2875/4885 |
| US-20250011288-A1 | RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | OPRK1 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.